Circulating Polymorphonuclear Myeloid-Derived Suppressor Cells (PMN-MDSCs) Have a Biological Role in Patients with Primary Myelofibrosis.
Rita CampanelliAdriana CaroleiPaolo CatarsiCarlotta AbbàEmanuela BoveriMarco PaulliRaffaele GentileMonica MorosiniRiccardo AlbertiniStefania MantovaniMargherita MassaGiovanni BarosiVittorio RostiPublished in: Cancers (2024)
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by a chronic inflammatory state that plays a relevant role in the disease pathogenesis (as proven by high levels of inflammatory cytokines with prognostic significance and by a persistent oxidative stress) and by extensive neoangiogenesis in bone marrow (BM) and spleen. Myeloid-derived suppressor cells (MDSCs) are immature cells that expand in patients with cancer, sepsis or chronic inflammation, favoring tumor onset and progression mainly through the decrease in immune surveillance and the promotion of neoangiogenesis. In this paper, we evaluated the presence of circulating MDSCs in PMF patients, the plasmatic factors involved in their mobilization/expansion and the correlations with laboratory, genetic and clinical parameters. The data indicated that MDSCs could have a relevant role in PMF as a new pathogenic mechanism contributing to explaining the phenotypic diversity observed during the clinical course of the disease, or a potential new target for personalized treatment.
Keyphrases
- induced apoptosis
- oxidative stress
- cell cycle arrest
- bone marrow
- endoplasmic reticulum stress
- end stage renal disease
- public health
- chronic kidney disease
- intensive care unit
- ejection fraction
- acute kidney injury
- dna damage
- gene expression
- machine learning
- mesenchymal stem cells
- prognostic factors
- big data
- ischemia reperfusion injury
- electronic health record
- patient reported outcomes
- human health
- high grade
- heat shock